LakeShore Biopharma Slashes Going-Private Offer Price to $0.066 Per Share, Down From $0.90
LSBCF is trading near its 52-week low of $0.028 (0.0% above the low).
Summary
LakeShore Biopharma has entered into an amended merger agreement for its going-private transaction, drastically reducing the per-share consideration from US$0.90 to US$0.066. This represents a significant 92.7% decrease from the original offer price. The amendment follows a revised proposal from the buyer group in March 2026. This development is highly negative for existing shareholders, as it locks in a substantially lower exit price for the company, which has a very small market capitalization and is trading near its 52-week low. The merger is now expected to close in the third quarter of 2026, pending shareholder approval.
At the time of this announcement, LSBCF was trading at $0.03 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $0.03 to $2.80. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: EQS.